Skip to content
  • Sunday, 26 July 2026
  • 2:10 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis
Pharmaceutical R&D

Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis

Teuku Ryan Jun 16, 2026 0

Simcere Pharmaceutical Group has forged a significant research collaboration with Stanford Medicine, aiming to unlock novel therapeutic avenues for idiopathic…

Read More
Molecular & Cell Biology

Microbial Partners Secretly Forge Ocean’s Calcium Carbonate, Reshaping Understanding of Marine Carbon Cycle

Angie Faith Jun 16, 2026 0

Scientists have uncovered compelling evidence suggesting that the microscopic life thriving within fish may play a far more significant role…

Read More
Pharmaceutical R&D

CVC Capital Partners and Groupe Bruxelles Lambert Launch $12.4 Billion Takeover Bid for Recordati, Signaling Potential Shift to Private Ownership

Teuku Ryan May 23, 2026 0

One of Italy’s few remaining publicly traded large pharmaceutical companies, Recordati, is on the cusp of transitioning to private ownership…

Read More
Pharmaceutical R&D

QIAGEN Digital Insights Partners with NVIDIA to Revolutionize AI-Driven Drug Discovery

Teuku Ryan May 20, 2026 0

The integration of NVIDIA’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ bioinformatics capabilities is poised to usher in…

Read More
Pharmaceutical R&D

Daiichi Sankyo Partners with Waiv to Accelerate Digital Pathology Biomarker Discovery for Antibody-Drug Conjugate Programs

Teuku Ryan May 7, 2026 0

In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…

Read More
Pharmaceutical R&D

Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology

Teuku Ryan Apr 18, 2026 0

Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…

Read More
AstraZeneca’s Targeted Treatment Offers New Hope for Stomach Cancer Patients in the UKNorthwestern University Engineers Develop Printed Artificial Neurons Capable of Direct Interaction with Biological Brain CellsNew Research Identifies Tanycytes as Critical Gatekeepers in the Clearance of Toxic Tau Proteins Associated with Alzheimer’s DiseaseScience News: A Century of Empowering Public Understanding of Science
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ